AI will benefit in that it
(i) produces more accurate results,
(ii) provide quicker turn-around time,
(iii) cut down human labour costs (but some level of human expertise is still required)
Where I think AI will make a difference is with the distributorship agreement with EnvoyAI and any partners.
It gives RHT a competitive advantage.
Q4 19 marks the about 9 mths since FDA approval and the EnvoyAI agreement. We should see some benefits trickling through but I think Q4 19 and Q1 2020 results will be the most exciting. As the clinical trials are approved and FerriSmart is used we should see a vast change on revenue.
What i like are these statements:
"the addition of a further 60 hospitals and imaging centresusing Resonance Health services either commercially or inclinical trials; and"
"Clinical trial work won this financial year resulted in a combined total dollar value of approximately US$1,530,200 (see ASXannouncements dated 23 August 2018, 29 October 2018, and 31 October 2018)."
- Forums
- ASX - By Stock
- Ann: Annual Report to shareholders
AI will benefit in that it(i) produces more accurate...
Featured News
Add RHT (ASX) to my watchlist
|
|||||
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.23M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 1400000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 0.051 |
2 | 169999 | 0.050 |
1 | 15566 | 0.049 |
3 | 1453427 | 0.048 |
1 | 80000 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 1400000 | 1 |
0.065 | 10000 | 1 |
0.067 | 12500 | 1 |
0.068 | 100000 | 1 |
0.070 | 150189 | 2 |
Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
Featured News
RHT (ASX) Chart |
Day chart unavailable